InvestorWire NewsRoom


Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent, Adds New Dimension to Development Strategy
July 28, 2021

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent, Adds New Dimension to Development Strategy

  • Digital therapeutics platform is proprietary to Cybin and the subject of the company’s 13th patent application
  • Company focused on utilizing, leveraging cutting-edge technologies to support drug-development candidates
  • Cybin is confident this added focus will better enable the evaluation of patient outcomes

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company, has taken another step forward in its strategic focus on progressing psychedelic therapeutics, with the filing of its 13th provisional patent application ( In addition to the patent filing, the company has also advanced the build-out of its digital therapeutics strategy.

“The digital therapeutics platform, which is proprietary to Cybin and the subject of the company’s 13th patent application, adds another dimension to the company’s development programs,” the announcement said. “The aim of utilizing and leveraging cutting-edge technologies to support drug-development candidates will be a top priority as both the industry and the company evolve.”

Already a recognized leader in progressing psychedelic therapeutics, Cybin is looking to evolve its programs beyond the psychedelic molecule into an eco-system that may potentially drive improved patient treatments through the advancement of its digital therapeutics development. In a strategic approach to accomplishing this objective, the company created a patient steering committee that, as part of the Cybin innovation team, is focused on the next phase of the digital therapeutics platform.

Cybin is confident this added focus will better enable the evaluation of patient outcomes through a highly secure, patient-centered data analytics platform for better pre- and post- psychedelic treatments. Other steps the company has taken recently to strengthen its presence in the market include collaborations with Kernel and its quantitative neuroimaging technology and Greenbrook TMS, the operator of 129 outpatient mental health service centers in the United States. The company is also working to advance other proprietary tools such as the EMBARK psychotherapy model. 

These efforts are all focused on Cybin’s commitment to building an advanced eco-system that can drive innovation from the psychedelic molecule, delivery of the molecule, quantitative testing of the molecule in patients to late-stage trials and one day potential patient treatments.

Cybin operates under the principle that psychedelic therapies offer a novel approach to mental health care that is focused on treating the underlying conditions and improving the patient experience and outcome. Recognizing that a paradigm shift in public policy has opened the door to new research and development in the field of psychedelic medicine and treatment regimens, the company is at the forefront of exploring all that psychedelics offer. “We believe that psychedelic therapies will be key to addressing the mental health crisis by transforming the treatment landscape,” the company states.

Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).